Peer-influenced content. Sources you trust. No registration required. This is HCN.
Healthgrades for Professionals
Although the 2020 numbers will likely look MUCH different, the Merritt Hawkins survey from 2019 showed increased gains from previous years. Of the 62 responses representing 93 hospitals, cardiovascular surgery drove the most revenue. Still, the outlook remains bleak post-pandemic.
Cardiology November 16th 2021
Blood Advances
This “Clinical Trials & Observations” report from Blood Advances (ASH) explores the implications of the recently approved anemia treatment luspatercept, which can now be prescribed in the second-line setting after erythropoiesis-stimulating agents (ESAs) have failed or for patients who are not eligible because of high serum erythropoietin (sEPO) levels. A downloadable visual abstract helps paint the picture as well.
Hematology March 16th 2021
Oncology Learning Network
Dr. David P. Carbone, Director of the Thoracic Oncology Center at Ohio State University, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases: “…the initial hope that PD‑1 inhibitors could be active on brain metastases has not been fully fulfilled, and the aggressive use of stereotactic radiation in that setting is useful.”
Oncology, Medical February 24th 2021